Literature DB >> 22604766

Use of once-weekly statin in combination with ezetimibe in a patient with mitochondrial disease.

Min Li1, Ahmad Al-Sarraf, Andre Mattman, Jiri Frohlich.   

Abstract

The authors describe a patient with personal and family history of muscle pains highly suggestive of mitochondrial disease. She presented with familial combined hyperlipidaemia with family history of premature coronary artery disease. After 4-week therapy of 5 mg of rosuvastatin once a week combined with 10 mg of ezetimibe daily, the low-density lipoprotein cholesterol level was markedly decreased from 3.88 to 2.82 mmol/l (27.3% reduction). She has experienced no adverse effects after 6 month treatment. The results suggest that the combination therapy of low-dose once-weekly rosuvastatin and daily ezetimibe could be used as an effective regimen for patients with mitochondrial disease.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22604766      PMCID: PMC3339188          DOI: 10.1136/bcr.12.2011.5369

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  13 in total

Review 1.  Mitochondrial disease.

Authors:  Anthony H V Schapira
Journal:  Lancet       Date:  2006-07-01       Impact factor: 79.321

2.  Statins provoking MELAS syndrome. A case report.

Authors:  Joseph E Thomas; Nora Lee; Paul D Thompson
Journal:  Eur Neurol       Date:  2007-03-26       Impact factor: 1.710

3.  Effects of once weekly rosuvastatin among patients with a prior statin intolerance.

Authors:  James M Backes; Patrick M Moriarty; Janelle F Ruisinger; Cheryl A Gibson
Journal:  Am J Cardiol       Date:  2007-06-18       Impact factor: 2.778

Review 4.  Drugs interfering with mitochondrial disorders.

Authors:  Josef Finsterer; Liane Segall
Journal:  Drug Chem Toxicol       Date:  2010-04       Impact factor: 3.356

5.  Efficacy and tolerability of once-weekly rosuvastatin in patients with previous statin intolerance.

Authors:  Steven P Kennedy; Gary P Barnas; Michael J Schmidt; Marcy S Glisczinski; Angela C Paniagua
Journal:  J Clin Lipidol       Date:  2011-05-13       Impact factor: 4.766

6.  Approach to the patient who is intolerant of statin therapy.

Authors:  Robert H Eckel
Journal:  J Clin Endocrinol Metab       Date:  2010-05       Impact factor: 5.958

Review 7.  Statin safety: a systematic review.

Authors:  Malcolm Law; Alicja R Rudnicka
Journal:  Am J Cardiol       Date:  2006-02-03       Impact factor: 2.778

Review 8.  Mitochondrial disorders: prevalence, myths and advances.

Authors:  D R Thorburn
Journal:  J Inherit Metab Dis       Date:  2004       Impact factor: 4.982

Review 9.  Statin adverse effects : a review of the literature and evidence for a mitochondrial mechanism.

Authors:  Beatrice A Golomb; Marcella A Evans
Journal:  Am J Cardiovasc Drugs       Date:  2008       Impact factor: 3.571

10.  Myotoxicity of lipid-lowering agents in a teenager with MELAS mutation.

Authors:  Stacey K H Tay; Salvatore Dimauro; Aileen Y W Pang; Poh-San Lai; Hui-Kim Yap
Journal:  Pediatr Neurol       Date:  2008-12       Impact factor: 3.372

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.